Will out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Bizengri is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by DGDA?

The DGDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DGDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Bangladeshi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Bangladesh Medical and Dental Council (BMDC) and the DGDA verifies the active license; the DGDA application records both the prescribing physician and the dispensing facility.

Can I receive Bizengri at home?

The dispensing facility must be Bangladeshi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Bizengri access in Bangladesh: the DGDA named-patient pathway

How patients in the People's Republic of Bangladesh legally obtain Bizengri (zenocutuzumab-zbco) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Bangladesh access Bizengri (zenocutuzumab-zbco) for advanced unresectable or metastatic pancreatic adenocarcinoma or non-small cell lung cancer harboring an NRG1 gene fusion through the DGDA named-patient pathway, a Directorate General of Drug Administration-administered mechanism that allows a Bangladeshi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in BDT.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Bizengri reaches patients in Bangladesh

Bizengri (zenocutuzumab-zbco, a humanised IgG1 bispecific antibody binding HER2 and HER3 with a Dock and Block design that prevents NRG1-driven HER2:HER3 heterodimerisation, from Merus N.V., FDA-approved 4 December 2024 under accelerated approval for adults with advanced unresectable or metastatic pancreatic adenocarcinoma or non-small cell lung cancer harbouring a neuregulin-1 gene fusion who have progressed on or after prior systemic therapy, label resource at accessdata.fda.gov) is not listed on the Directorate General of Drug Administration registered imported drugs database at dgdagov.info/registered-imported-drugs as of 2026-06-01. Bangladesh patients access the medicine under the case-by-case Permission to Import Unregistered or Foreign Medicine for Personal or Institutional Use, administered by DGDA under Section 13 of the Drugs (Control) Ordinance 1982 read with Section 14A (which prohibits prescription of unregistered medicines absent DGDA permission), ordinance at bdlaws.minlaw.gov.bd/act-623. The DGDA Guidelines on Import Procedures for Medical Products are published at dgdagov.info guidance, with the Bangladesh Trade Portal Registration for Foreign Medicine procedure at bangladeshtradeportal.gov.bd. The application is filed to the Director General, DGDA, by the treating medical oncologist or institutional importer, with a Bangladesh Medical and Dental Council registered prescription, the NRG1-fusion next-generation sequencing report from a molecular pathology laboratory, prior systemic therapy history, the patient's national identification, and a pro-forma invoice. No public DGDA service-level agreement for processing time is documented. Each consignment requires a fresh DGDA permission letter presented to Bangladesh Customs at port of entry.

Where Bizengri is dispensed in Bangladesh

Bizengri is administered as a 750 mg intravenous infusion every two weeks per the FDA label, with infusion-related reaction monitoring and a boxed warning for embryo-fetal toxicity. Dispensing routes through medical oncology services at tertiary cancer hospitals with the infusion suite capacity, the NRG1-fusion molecular testing infrastructure, and the surveillance capacity for infusion reactions, interstitial lung disease and pneumonitis, hepatic, and cardiac monitoring per the FDA label. The National Institute of Cancer Research and Hospital Dhaka, the only specialised government tertiary cancer hospital, hosts Medical Oncology and the relevant disease-site services for pancreatic adenocarcinoma and non-small cell lung cancer, at nicrh.gov.bd. Bangabandhu Sheikh Mujib Medical University Dhaka operates Medical Oncology and Thoracic Medicine services, at bsmmu.edu.bd. Dhaka Medical College Hospital and Chittagong Medical College Hospital provide general tertiary oncology. Ahsania Mission Cancer & General Hospital Dhaka serves as a charitable tertiary oncology centre. Among private tertiary nodes, Square Hospitals Dhaka, United Hospital Dhaka, Evercare Hospital Dhaka, and Labaid Specialized Hospital Dhaka publish medical oncology consultant rosters and routinely handle named-patient oncology imports. NRG1-fusion testing in Bangladesh is concentrated at university and private molecular pathology laboratories; documentation of the testing laboratory and the NGS panel used is part of the DGDA filing.

What Bizengri costs in Bangladesh

Merus N.V. has reported list pricing for Bizengri in launch disclosures at approximately USD 19,800 per 750 mg infusion vial, with an every-two-week dosing schedule yielding approximately USD 514,800 per year at the labelled regimen, sourced from Merus disclosures and Drugs@FDA at accessdata.fda.gov. No public local-currency benchmark for Bizengri in BDT is observed on DGDA at dgda.gov.bd, in Bangladesh hospital pharmacy reporting, or in NICRH pricing reporting as of 2026-06-01, consistent with the drug not being DGDA-registered; do not estimate. Price snapshot: 2026-06-01. Cost layers stacked on the drug cost include international validated 2 to 8 degree Celsius cold-chain freight (Bizengri is a refrigerated biologic per the FDA label), DGDA permission and customs handling, the oncology infusion suite's administration fee, the NRG1-fusion molecular pathology assay fee where the laboratory is the dispensing centre rather than an upstream lab, and the Reserve Meds concierge fee itemised separately on every firm quote. The non-commercial-import customs threshold of USD 7,000 per shipment referenced in the US Department of Commerce country guide at trade.gov Bangladesh guide is exceeded by a typical Bizengri shipment; DGDA permission is the binding requirement.

Funding and access barriers for Bizengri in Bangladesh

Bangladesh has no nationwide universal health insurance scheme as of 2026-06-01. The Shasthyo Surokhsha Karmasuchi pilot operates in selected upazilas for below-poverty-line families; coverage of unregistered specialty oncology imports under SSK has not been documented. The National Institute of Cancer Research and Hospital and Bangabandhu Sheikh Mujib Medical University provide subsidised inpatient oncology care funded through Ministry of Health and Family Welfare budgets; specialty named-patient targeted-therapy oncology biologics at originator pricing are not part of routine MOHFW procurement. The Honourable Prime Minister's Welfare Fund and the Honourable Prime Minister's Special Fund consider case-by-case grants for high-cost foreign-sourced cancer treatment; NRG1-fusion-targeted bispecific antibodies are not subjects of any public bulletin from these funds as observed at the snapshot date. Bangladesh private insurers including Pragati Life Insurance, Delta Life Insurance, MetLife Bangladesh, Green Delta Insurance, Pioneer Insurance, and the state-owned Sadharan Bima Corporation cover specialty oncology variably; private health insurance penetration is low. Bangladesh's out-of-pocket share of total health expenditure consistently sits above 65 percent per WHO and National Health Accounts reporting. The dominant funding pattern for a Bizengri case is family self-pay, supported where applicable by remittance from family members in the Gulf, North America, or the UK and by charitable funding through institutions like Ahsania Mission Cancer & General Hospital. The Merus Compassionate Use programme operates outside the US for selected cases; case-by-case enquiry with Merus through the treating oncologist may be appropriate. The NRG1-fusion testing requirement is a logistical barrier; turnaround time at Bangladesh molecular pathology laboratories or referral to India or Singapore for testing is a planning consideration.

Recent regulatory and access news for Bizengri

The DGDA notices feed at dgda.gov.bd/all-categories-notices has not posted a zenocutuzumab-specific notification over the last 12 months as of 2026-06-01. DGDA published the Guideline for Quality Assurance of Locally Sourced Medical Products on 2025-01-14 at dgda.portal.gov.bd policy, which addresses local manufacturing rather than personal-import oncology biologic permissions. The Government of Bangladesh has continued public consultation on a planned new medicine-regulation law to replace the 1982 Ordinance, reported by Dhaka Tribune at dhakatribune.com new law on medicine regulation; the law had not been gazetted at the snapshot date. The US FDA approved Bizengri on 4 December 2024 under accelerated approval based on objective response rate and duration of response; the confirmatory trials continue under the manufacturer's post-marketing commitment. No relevant local bulletins on Bizengri or NRG1-fusion-targeted oncology therapies in Bangladesh in the last 12 months have been observed as of 2026-06-01.

Where Reserve Meds fits in Bizengri cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DGDA, and we do not replace your dispensing pharmacy. For Bizengri specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Bangladesh, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Bizengri case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DGDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Bangladeshi tertiary specialty care concentrates at Square, Apollo Imperial, United, Evercare, and Labaid in Dhaka; the DGDA named-patient import authorisation is the standard mechanism for unregistered specialty medicines and is typically filed by the treating consultant at one of these centres.

Next step

If your Bangladeshi physician has prescribed Bizengri and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Bizengri case Or message us on WhatsApp